SCHEMBL24371884

SCHEMBL24371884

CC(C)c1cccc2nnn(C(C)C)c12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.47
ALDH1A1 P00352 2/20 0.47
CYP2C19 P33261 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
LMNA P02545 2/20 0.37
GABRA1 P14867 3/20 0.36
HPGD P15428 2/20 0.36
TSHR P16473 2/20 0.36
GABRG2 P18507 2/20 0.36
GABRB3 P28472 2/20 0.36
GABRB2 P47870 2/20 0.36
FAAH O00519 1/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
CYP3A4 P08684 1/20 0.36
GABRB1 P18505 1/20 0.36
PTGS1 P23219 1/20 0.36
SLC6A2 P23975 1/20 0.36
HTR2C P28335 1/20 0.36
GABRA5 P31644 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18368377 0.80 KEAP1 (0.46) CYP1A2ALDH1A1CYP2C19SMN1; SMN2LMNA
SCHEMBL29265210 0.75 ALDH1A1 (0.47) CYP1A2ALDH1A1CYP2C19SMN1; SMN2LMNA
SCHEMBL12913584 0.71 GRM2 (0.37) CYP1A2ALDH1A1CYP2C19SMN1; SMN2LMNA
SCHEMBL1083846 0.69 ALDH1A1 (0.58) CYP1A2ALDH1A1CYP2C19SMN1; SMN2HPGD
SCHEMBL10780482 0.68 CYP1A2 (0.40) CYP1A2ALDH1A1CYP2C19SMN1; SMN2LMNA
SCHEMBL23308487 0.68 GABRA1 (0.36) CYP1A2ALDH1A1CYP2C19LMNAGABRA1
SCHEMBL12831721 0.67 CRHR1 (0.37) CYP1A2ALDH1A1SMN1; SMN2LMNAGABRA1
SCHEMBL24474514 0.66 CLK1 (0.39) CYP1A2ALDH1A1CYP2C19SMN1; SMN2LMNA
SCHEMBL19131139 0.66 ALDH1A1 (0.45) CYP1A2ALDH1A1CYP2C19SMN1; SMN2LMNA
SCHEMBL12831727 0.66 TSHR (0.42) CYP1A2ALDH1A1SMN1; SMN2LMNAGABRA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240018102-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY Lhotse Bio, Inc (US) 2024-01-18 US disclosed
US-20240018102-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY Lhotse Bio, Inc (US) 2024-01-18 US disclosed
WO-2022083703-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY LHOTSE BIO, INC. (US) 2022-04-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240018102-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY LPAR1, LPAR2, LPAR5 CYP1A2 1941/4885ALDH1A1 1641/4885CYP2C19 2564/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.